Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
Nivolumab with ipilimumab is approved by the USFDA for unresectable or metastatic MSI-H or dMMR colorectal cancer
The FDA has approved nivolumab + ipilimumab for unresectable/metastatic MSI-H or dMMR colorectal cancer. This immunotherapy combination offers new hope for advanced CRC patients with...
Durvalumab is approved by the USFDA for muscle invasive bladder cancer
The USFDA has approved durvalumab (Imfinzi) for muscle-invasive bladder cancer (MIBC), offering a new immunotherapy option for cisplatin-ineligible patients. Discover how this PD-L1 inhibitor improves...
The FDA has broadened the indication for Pluvicto to include metastatic castration-resistant prostate cancer
The FDA has broadened Pluvicto’s approval to include metastatic castration-resistant prostate cancer (mCRPC). This PSMA-targeted radioligand therapy offers new hope for advanced prostate cancer patients....
Cabozantinib is approved by the USFDA for adults and pediatric patients 12 years of age and older with pNET and epNET
The USFDA has approved cabozantinib (Cabometyx®) for progressive pancreatic & extra-pancreatic neuroendocrine tumors (PNET/EPNET) in adults & pediatric patients (12+). This targeted therapy offers new...
Pembrolizumab is approved by the USFDA for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)
The USFDA has approved pembrolizumab for HER2-positive gastric/gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥1. This immunotherapy offers new hope for advanced gastric cancer patients. Learn...
Gene Therapy for Gaucher’s Disease in China
Gene therapy for Gaucher’s disease in China offers a potential cure by correcting the faulty GBA gene. Using viral vectors or CRISPR, this treatment could...
Gene Therapy for Wilson’s Disease in China
Gene therapy for Wilson’s disease in China offers a groundbreaking cure by correcting the faulty ATP7B gene. With advanced viral vector and CRISPR-based treatments, patients...
Gene Therapy for Phenylketonuria in China
Gene therapy for phenylketonuria (PKU) in China represents a groundbreaking advancement in treating this rare genetic disorder. By delivering a functional PAH gene via viral...
Best Cancer Hospitals in China 2025
Best Cancer Hospitals in China China has become a world leader in medical innovation, especially in oncology. The nation has, over the past decade,...
Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor...
Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new...
Mirdametinib is approved by the USFDA for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
The FDA has approved mirdametinib for adult and pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The MEK inhibitor addresses tumor...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.